Agenus (AGEN) : 4 brokerage houses believe that Agenus (AGEN) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Agenus (AGEN) : Average target price received by Agenus (AGEN) is $7.67 with an expected standard deviation of $2.08. The most aggressive target on the stock is $10, whereas the most downbeat target is $6. 3 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy.
Agenus (NASDAQ:AGEN): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.76 and $4.65 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.84, notching a gain of 2.76% for the day. The total traded volume was 1,125,135 . The stock had closed at $4.71 on the previous day.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).